Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats. (3rd July 2022)
- Record Type:
- Journal Article
- Title:
- Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats. (3rd July 2022)
- Main Title:
- Predictive marker for exposure-driven haematological toxicity of tegafur-uracil and proposed modified-dosage regimen by pharmacometric approach in rats
- Authors:
- Kobuchi, Shinji
Matsui, Megumi
Ito, Yukako - Abstract:
- Abstract: Myelosuppression is a dose-limiting toxicity of uracil-tegafur (UFT), which contains uracil and the 5‑fluorouracil prodrug tegafur, and inhibits the continuation of chemotherapy, causing treatment failure. A proper dosing strategy to avoid severe myelosuppression-induced discontinuation of chemotherapy is required. Plasma drug concentrations were determined in rats after single oral UFT administration of 15, 30, or 60 mg/kg. Blood cell counts were also measured after oral UFT administration for 5 days. Pharmacokinetic-toxicodynamic (PK-TD) modelling and simulation were performed to describe the time-course alterations in the blood cell counts. Severe neutropenia was observed in rats treated with 60 mg/kg UFT on day 7. A significant decrease in neutrophil counts from baseline levels prior to UFT administration was observed on day 3, whereas leukocyte and lymphocyte counts decreased on day 7. The semi-physiological PK-TD model successfully captured alterations in neutrophil counts after UFT administration, whereas the model could not well describe the platelet, leukocyte, and lymphocyte counts, possibly due to the absence of severe thrombocytopenia, leukocytopenia, and lymphocytopenia, respectively. Neutrophils are sensitive markers for estimating the grade of haematological toxicity of UFT, and a PK-TD model might be an attractive tool for quantitatively evaluating the onset and degree of myelosuppression.
- Is Part Of:
- Xenobiotica. Volume 52:Number 7(2022)
- Journal:
- Xenobiotica
- Issue:
- Volume 52:Number 7(2022)
- Issue Display:
- Volume 52, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 52
- Issue:
- 7
- Issue Sort Value:
- 2022-0052-0007-0000
- Page Start:
- 697
- Page End:
- 706
- Publication Date:
- 2022-07-03
- Subjects:
- Preclinical pharmacokinetics -- pharmacokinetic-pharmacodynamic model -- cancer chemotherapy -- myelosuppression -- 5-fluorouracil -- UFT
Metabolism -- Periodicals
Drugs -- Physiological effect -- Periodicals
Food additives -- Periodicals
Chemicals -- Physiological effect -- Periodicals
Biochemistry -- Periodicals
Pharmaceutical Preparations -- metabolism -- Periodicals
Metabolism -- Periodicals
574.133 - Journal URLs:
- http://informahealthcare.com/journal/xen ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/00498254.2022.2142696 ↗
- Languages:
- English
- ISSNs:
- 0049-8254
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9367.020000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24661.xml